Host genomic influences on HIV/AIDS

Stephen J O’Brien and Sher L Hendrickson

Abstract
The AIDS era has seen multiple advances in the power of genetics research; scores of host genetic protective factors have been nominated and several have translated to the bedside. We discuss how genomics may inform HIV/AIDS prevention, treatment and eradication.

Introduction
Thirty-one years have passed since reports of severely immune-compromised gay men in San Francisco and New York first drew attention to the AIDS epidemic [1,2]. It took 3 years to identify the cause as human immunodeficiency virus (HIV)-1, a lentivirus that subverts the lymphoid system to become viral factories producing 1-2 billion virions per day. HIV-1 infects and destroys CD4-bearing lymphocytes, decreasing the victim’s ability to overcome normally innocuous agents such as Pneumocystis, Candida, cytomegalovirus and a score of other opportunistic infections (Box 1). Left untreated, these infections and certain rare cancers contribute further to the immune system collapse and to the demise of the patients. An effective vaccine is yet to be developed, and anti-retroviral drugs are not ideal since they do not work well for all patients, can generate adverse side effects and do not eliminate the virus from an infected patient. Since the first reports of AIDS in 1981, the world has seen more than 60 million cases of HIV infections, and 30 million victims have died as a consequence, 90% of them in the developing world [3].

The genomic era began eleven years ago with the release of the draft sequence of the human genome. A complete human gene set and DNA sequence was available to help combat the more inscrutable deadly chronic and infectious diseases [4], and this has enabled the investigation of HIV/AIDS using the new tools of genomics. AIDS exhibits abundant epidemiological heterogeneity, much of which could be attributed to host genetic factors. Beginning in the early 1980s, epidemiologists began collecting longitudinal cohorts of at-risk AIDS populations to describe that heterogeneity. Many collaborated with geneticists, who used population genetics-based association analyses to uncover genes with natural variants that exerted an effect on HIV infection, on the dynamics of AIDS progression, and on the results of highly active anti-retroviral therapy (HAART). This review will attempt to update the status of discovered host genetic influences on stages of AIDS beyond the informative reviews that have appeared to date [5-10]. We will highlight those host gene influences that are credible, replicated and implicated in AIDS disease, and we will discuss their clinical relevance in stemming the spread of HIV.

Candidate AIDS restriction genes: the case of CCR5-∆32
Before the first of ten HIV-AIDS genome-wide association studies (GWAS) appeared [11], single nucleotide polymorphism (SNP) variants in numerous candidate genes were suggested as being associated with HIV or AIDS in patients. Several hundred candidate gene SNPs were tested for association with AIDS progression and for HIV transmission. Over 35 plausible AIDS restriction genes (ARGs) have been identified (Table 1). Their discovery, replication and functional interpretation have been reviewed in depth, and these reviews should be consulted to appreciate the details uncovered around each ARG discovery [5-10].

The first and perhaps most provocative ARG involved the description of CCR5-∆32, a 32 base pair deletion frameshift mutation that truncates C-C chemokine receptor 5 (CCR5), the HIV entry receptor on lymphoid cells [12-14] (see Box 2 for a discussion of the origin of this mutation). Epidemiological studies showed that individuals homozygous for CCR5-∆32 had a 100-fold reduction in HIV infection incidence: the genotype seems to confer near complete protection from HIV infection (Figure 1). Individuals in large cohort studies that are heterozygous for CCR5-∆32, although susceptible to infection, consistently have a delayed onset of AIDS by two to four years, likely due to the diminishing onset of
AIDS is one of the most intensively studied diseases in history, providing not only a rich description of the steps in steady progression to immune collapse and death, but also discrete stages that can be investigated for host genetic influence. The process begins when a person becomes exposed to HIV-1, which can occur through sexual contact with an infected partner, intravenous injection with contaminated needles used to deliver addictive drugs, or receipt of contaminated blood or blood products (for example, clotting Factor VIII and IX in the case of hemophiliacs). Once an individual becomes infected, HIV-1 seeks out and overtake CD4-bearing T-lymphocytes to produce a struggle between viral production (tracked as the viral load – the virus titer in circulating blood) and immune defenses that struggle to control viral proliferation in the beginning weeks. With more than 1 billion new HIV copies produced each day by an acutely infected person, and with new mutational variants arising at a rate of one every second virus copy, immune control is no mean feat. Nonetheless, in most infected people the viral load settles to a chronic plateau level, which varies among individuals from $1 \times 10^3$ to $1 \times 10^6$ virions/ml (known as the viral set point). Over time the virus gradually destroys the CD4 lymphocytes and the blood count drops to below 200 CD4$^+$ cells/mm$^3$. The time in which CD4 cell depletion occurs can vary from within a year of infection to more than 20 years later, with the mean time at approximately 10 years post infection. Once the CD4 cell counts drop, the patients succumb to a variety of normally innocuous infections (Candida, Pneumocystis carinii, cytomegalovirus, herpes, tuberculosis and others) and to rare cancers such as Kaposi’s sarcoma and B cell lymphomas. If left untreated, these infections and cancers almost invariably lead to death.

In 1996, a powerful triple drug anti-retroviral therapy was initiated and offered a milestone in AIDS treatment and prognosis. In most patients receiving this treatment, known as highly active anti-retroviral therapy (HAART), the viral load drops to below detectable levels. As promising as these treatments became, there were caveats. Many people (20 to 40%) do not tolerate the drugs and develop adverse reactions. The treatment does not clear HIV from many tissues, and suspension of treatment therefore invariably results in viral load rebound in the blood. Last, in spite of viral replication repression, there is still slow viral-induced pathology and so many patients continue, albeit more slowly, to progress to AIDS and death.

Genetic researchers noted epidemiological differences in four principal stages: (1) HIV acquisition of infection; (2) the rate of progression to AIDS among HIV-infected individuals; (3) the nature of the AIDS-defining condition displayed; and (4) the outcome of HAART, viral load suppression, adverse events and AIDS progression post-treatment [5-10] (Table 1). Case–control and survivor analyses (in the form of Cox proportional hazards models) parsed into alternative SNP alleles or genotypes allow for statistical comparison for differences in patient populations that exhibit better or worse outcome for each stage, leading to gene/SNP association.

Source: An and Winkler [5], reproduced with permission.
Table 1. Candidate AIDS restriction genes

| Year | Gene symbol | Allele | Mode      | Effect               | Citation(s) |
|------|-------------|--------|-----------|----------------------|-------------|
| 1996 | CCR5        | Δ32    | Recessive | Prevents infection   | [12-14]     |
| 1996 | CCR5        | Δ32    | Dominant  | Delays AIDS          | [12]        |
| 1997 | CCR2        | 64I    | Dominant  | Delays AIDS          | [80]        |
| 1998 | CCR5P       | P1     | Recessive | Accelerates AIDS     | [81]        |
| 1998 | SDF1        | 3'A    | Recessive | Delays AIDS          | [82]        |
| 1999 | CCR5        | Δ32    | Dominant  | Prevents lymphoma    | [15]        |
| 1999 | HLA         | A,B,C     | Co-dominant | Accelerates AIDS | [83]        |
| 2000 | IL10        | 5'A    | Dominant  | Limits infection     | [84]        |
| 2001 | HLA         | B*35Px  | Co-dominant | Accelerates AIDS | [85]        |
| 2002 | RANTES      | −403A  | Dominant  | Accelerates AIDS     | [86]        |
| 2002 | KIR         | 3D1    | Epistatic | Delays AIDS          | [28,29]     |
|       |             |        |           |                      |             |
| 2003 | EOTAXIN-MCP1 | Hap7   | Dominant  | Enhances infection   | [87]        |
| 2003 | HLA         | B*57    | Co-dominant | Delays AIDS          | [88]        |
| 2003 | IFNG        | 179T   | Dominant  | Accelerates AIDS     | [89]        |
| 2003 | CXCR6       | E3K    | Dominant  | Accelerates PCP      | [90]        |
| 2004 | APOBEC3G    | H186R  | Recessive | Accelerates AIDS     | [91]        |
| 2004 | DC5IGN      | −336T  | Dominant  | Decreases infection  | [92]        |
| 2006 | HLA         | B27    | Co-dominant | Delays AIDS          | [93]        |
| 2006 | TSG101      | Hap2   | Dominant  | Accelerates AIDS     | [94]        |
| 2006 | TRIM5       | Hap4   | Dominant  | Increases infection  | [95]        |
| 2007 | CUL5        | HapI   | Co-dominant | Accelerates CD4 loss | [96]        |
| 2007 | PPTA (cyclophilin A) | SNP-4 | Dominant  | Accelerates AIDS     | [97]        |
| 2007 | HLA         | Bv4    | Dominant  | Reduces HIV          | [98]        |
|       |             |        |           |                      |             |
| 2008 | MYH9        | End Stage Renal Disease |               |                      | [31]        |
| 2008 | MYH9        | HIV FSGN |                      |                      | [30]        |
| 2008 | mtDNA       | Hap-J, U5a | Dominant | Accelerates AIDS     | [56]        |
| 2008 | mtDNA       | Hap-H  | Dominant  | Increases            | [55]        |
|       |             |        |           | Lipoatrophy post HAART |             |
|       |             |        |           |                      |             |
| 2008 | mtDNA       | Hap-J  | Dominant  | Delays CMV-NRD       | [99]        |
| 2009 | HCPS5       | T>C, rs2395029 | Dominant | HIV set point       | [33]        |
| 2009 | HLA         | 9264942 | Dominant  | HIV set point       | [33]        |
| 2009 | PROX1       | Hap-CGT | Recessive | Delays AIDS progression | [37]    |
| 2009 | APOBEC3B    | ΔV_7   | Recessive | Increases infection  | [100]       |
| 2010 | PECI        | G      | Dominant  | Accelerates AIDS     | [52]        |
| 2010 | ACSM4       | A      | Co-dominant | Delays AIDS          | [52]        |
| 2010 | NOD2        | T      | Dominant  | Increases infection  | [57]        |
| 2010 | IDH1        | C      | Dominant  | Prevents infection   | [57]        |

All these genes were discovered or validated using the NCI-Laboratory of Genomic Diversity. Eight AIDS cohorts comprising more than 10,000 study participants were used in these studies from 1985 to 2011 [5,10,79,101].
Box 2. The origins of the CCR5-Δ32 mutation in human populations

The CCR5-Δ32 allele occurs at a relatively high frequency in Europe (about 10%), but is completely absent in native African and Asian people. This distribution, plus the high incidence of amino acid-altering mutations (about 80%) among all SNP variants in the CCR5 locus, lent support to the idea that CCR5-Δ32 was likely the object of strong selective pressures favoring CCR5-Δ32 frequency elevation in European ancestors [18,71,72]. The extended haplotype of SNPs around CCR5-Δ32 is about 1,000 kb, 100 times longer than the average haplotype size in Europeans, suggesting a recent mutational origin of CCR5-Δ32 and possibly a selective advantage of CCR5-Δ32 carriers [72-74].

But what was the selective pressure? It was likely a global deadly epidemic that CCR5-Δ32 carriers were resistant to, but it could not have been HIV/AIDS since this epidemic emerged in the early 20th century, too recent to account for the high frequency of CCR5-Δ32 in European populations. An evolutionary computation based upon the length of the extended CCR5 haplotype was used to estimate that the date of the last selective elevation of CCR5-Δ32 was about 700 years ago [72]. This calculation raised the prospect that survivors of the Black Death (in which bubonic plague killed some 25,000,000 Europeans in 1348–1353 CE) had a role in favoring the elevation of CCR5-Δ32.

A functional demonstration that cultured cells from Ccr5–/– knockout mice (equivalent to CCR5-Δ32/Δ32 homozygous people) show a 30-fold reduction in sensitivity to infection by Yersinia pestis, the plague bacillus, compared with Ccr5+/+ normal mice [75] lends credence to this provocative explanation. A more detailed narrative of the still unproven plague hypothesis is presented in [76].

There are alternative interpretations as to the cause of CCR5-Δ32-selective elevation (some have proposed that anthrax, smallpox, Ebola and other contagions played a selective role in the rise of CCR5-Δ32 in medieval Europe) and even for Black Death etiology. Whether the direction of the allele frequency cline (gradient) across Europe tracks the plague progression or whether plague mortality was large enough to elevate CCR5-Δ32 sufficiently have been raised in critiques of the plague/CCR5-Δ32 hypothesis. Nonetheless, the functional connection of a CCR5 receptor requirement for Yersinia infection, the coalescent date of 700 years for CCR5-Δ32 haplotype origins, the enormous toll of the Black Death (an estimated 25 million Europeans – one-third of the population – perished by the Black Death) and the multiple plague episodes across Europe tracing from the Justinian plague (541 to 542 CE) to the 17th-century Great Plague of London (1664 to 1666 CE) all lend support to plague being a principal selective pressure on CCR5-Δ32 [18,72,76].

The CCR5 function is dispensable in the human genome, a notion supported by the redundancy of other human chemokine receptors that also interact with specific chemokine ligands of CCR5 [17]. The knowledge that CCR5 is required for HIV-1 infection of lymphoid cells in exposed people, plus the suspicion that CCR5 function is dispensable for good health [18] (see Box 3), stimulated pharmaceutical development of a dozen new anti-AIDS treatments termed HIV entry inhibitors. Entry inhibitors were designed to interfere with HIV–CCR5 cell receptor binding as a block to HIV pathogenesis [19-21]. Two powerful HIV entry inhibitors, enfuvirtide (T20) and maraviroc, were approved for AIDS patient treatment by the Food and Drug Administration (FDA) in 2003 and 2007, respectively. The rapid development of this new avenue for AIDS therapy was clearly encouraged by the characterization of HIV resistance in CCR5-Δ32 homozygotes (the 30-plus other HAART drugs all target HIV-encoded enzymes: reverse transcriptase – targeted by both nucleotide reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors – and the HIV-encoded protease).

A remarkable example of CCR5-Δ32 clinical translation to the bedside involves the treatment of Timothy Leigh Brown, dubbed the ‘Berlin patient’ [22]. Brown was a 25-year-old American living in Berlin in 1995 when he was diagnosed with HIV infection. Despite receiving sporadic anti-HIV medication, his condition deteriorated and he was diagnosed with acute myelogenous leukemia in 2006. His AIDS clinician, Gero Hutter, prescribed a stem cell transplant of healthy HIV-negative donor lymphocytes following x-irradiation of his lymphoid system [23]. Hutter searched the European bone marrow databases to find an HLA-matched donor who was homozygous for CCR5-Δ32, so as to block HIV transmission to the donor graft cells. After the stem cell transplant in February 2007, Brown’s anti-retroviral treatment was suspended to allow the graft to grow, though monthly blood tests were initiated to detect the inevitable latent HIV rebound. But rebound never occurred. Three years later, Hutter and his team reported that Brown had consistently tested negative for circulating plasma HIV since the transplant [23]. Subsequent rather invasive biopsies of multiple tissues (plasma, gut, brain, testis, liver) using hyper-sensitive virus assays were also negative, indicating that his body had been cleared of replicating HIV, the first such event recorded in history [22-24]. Though no one is certain that each and every one of the scores of human tissues that can become infected with HIV are clear in Mr Brown’s body, as of now – five years later – his case is being heralded as the single documented clearance or apparent cure of HIV infection.

Bone marrow and stem cell transplants are of limited promise as a universal therapy. They are expensive (circa US$250,000) and not very safe, primarily because even HLA-matched donors are immunologically allogeneic (that is, non-self). The immune system of the recipient must be destroyed, deadly graft versus host reaction against the host is common, and a dangerous transplantation therapy must be followed by a lifelong
regimen of anti-rejection therapies. A promising alternative to this may be immunologically syngeneic (self) grafts with CCR5 knockout strategies. Carl June and Bruce Levine at University of Pennsylvania have developed such a protocol using zinc finger targeted knockout of normal CCR5 genes in HIV-infected patients [25]. Twelve such patients have been infused with their own-engineered CCR5–/– lymphocytes. The results are promising to date, with donor cell reconstitution observed and few safety issues encountered, and several patients remained plasma HIV-negative several months post transplant infusion.

News of the Berlin patient’s amazing recovery travelled quickly in the AIDS research community and beyond. Attention was also paid to the fascinating secondary observation that the Berlin patient has never developed graft versus host disease (GVHD), a deadly reaction that afflicts 30–50% of bone marrow and stem transplant recipients. Transplant researchers at University of Pennsylvania reasoned that perhaps the CCR5-Δ32 genotype of the Berlin patient’s transplant donor might have prevented his GVHD; this would affirm a role for intact CCR5 in GVHD. The availability of safe and FDA approved CCR5 antagonist drugs for AIDS, such as maraviroc, prompted a Phase I and II clinical trial to see if maraviroc-treated transplant patients might avoid GVHD, as with the Berlin patient [26]. A group of 38 cancer patients treated with maraviroc post-transplant demonstrated a dramatic reduction in GVHD without any major adverse side effects. If confirmed by a larger Phase III trial, CCR5 may therefore be implicated as a key player in cancer treatments as well as AIDS therapies. It should be noted that maraviroc is considered to be a safe drug and that CCR5-Δ32/Δ32 homozygotes are generally healthy. If such bold new therapies do prove efficacious, they will stand upon the findings of the CCR5-Δ32/Δ32 homozygotes’ genetic resistance to HIV acquisition and the apparent success with the Berlin patient.

Figure 1. Influence of CCR-Δ32 on different stages of HIV AIDS. (a) HIV transmission/acquisition. The frequency (percentage) of CCR-Δ32 genotypes among HIV infected versus HIV uninfected people in cumulative AIDS cohorts (total n = 17,214 study participants) [12-14,79,101]. (b) AIDS progression in HIV-infected people. Kaplan–Meier survival curves comparing the rate of AIDS onset in CCR+/+ versus CCR5+Δ32 [12,79,101]. (c) Progression to AIDS post HAART therapy. Kaplan–Meier survival curves comparing the rate of AIDS onset in CCR+/+ versus CCR5+Δ32 [16].
AIDS resistance genes beyond CCR5

Each of the genes listed in Table 1 has the potential to have a detailed narrative such as that described for CCR5-Δ32. For example, HLA allelic resistance and susceptibility to AIDS progression is well accepted, and at least one HLA genotype, HLA-B*5701, seems to predispose carriers to a severe immunological disorder (fever, gastrointestinal and respiratory distress) when they are treated with the nucleoside reverse transcriptase inhibitor abacavir [27]. HLA genotyping is now a prerequisite to abacavir prescription. Epistatic interactions of HLA class I protein products and the killer immunoglobulin cluster KIR ligands (chr19) are powerful, but have not yet informed clinical practice [28,29].

SNP variants within loci that exert powerful anti-HIV restrictions in vitro and against other viruses (TRIM5, APOBEC, TSG101, CLIL5) have shown modest effects on AIDS progression in association studies (Table 1). Unlike CCR5-Δ32, which confers a complete loss of function mutation, the consequence of most other Table 1 SNP variants are limited by quantitative influences on gene action. An important predictive influence on HIV-associated nephropathy, particularly among African Americans, appears to be associated with multi-SNP haplotypes within the MYH9 (non-muscle myosin IIA) gene [30,31]. The risk alleles are quite common in African Americans but rare in European Caucasians, which explains a 20-fold higher risk for HIV-associated nephropathy in African Americans. Taken together, combining functional data that connects ARG variants directly to HIV pathology, robust statistical gene SNP associations and clinical translation has improved our understanding of diagnosis, pathogenesis, treatment and ablation of AIDS.

HIV/AIDS GWAS

Unlike association studies of candidate genes, GWAS scan the entire genome with hundreds of thousands (if not millions) of common human SNPs to discover genome regions that statistically associate with explicit AIDS endpoints in large cohort studies (Box 1). Fellay et al. [11] reported the first AIDS GWAS in 2007. Their study tracked the HIV set point (mean plasma viral RNA level over several months once the immune system has settled to a steady state level after initial spikes in virus upon HIV infection; see Box 1) in 486 European AIDS patients from the Euro-Center for HIV/AIDS Vaccine Immunology (CHAVI) cohort that were genotyped with an Illumina 550,000 SNP array. Fellay et al. discovered three genome-wide significant (after Bonferroni correction for multiple SNP tests; <9.3 × 10^{-8}) SNPs nested within the HLA complex, including a proxy-SNP in linkage disequilibrium (LD) HLA-B*5701, a known protective influence on AIDS progression. Since then ten additional GWAS using different cohorts, and different AIDS stages (phenotypes), arrays and numbers of SNPs, have appeared [32-41]. The combined GWAS have consistently fingered HLA SNPs, but agreed on little else. Additional GWAS-based gene discoveries outside HLA appear robust, but they have seldom included the candidate genes listed in Table 1, nor have the implicated gene associations been replicated by independent studies. Further, the fraction of the epidemiological variance of AIDS progression that individual or combined GWAS discovered genes can explain falls between 10% and 20% for AIDS progression and far less for other stages of AIDS (for example, HIV acquisition, HAART outcomes, and so on) [10,11,40]. Rediscovering HLA and the low level of explanatory variance were disappointing to the AIDS community given the promise of GWAS for resolving gene determinants in other complex diseases. The advantages of GWAS over candidate gene studies are well known: (1) they can reveal genes we may not have considered since they survey the entire genome; (2) the patterns of LD allow for haplotype-based closing in on
the causal or operative SNP variant; (3) copy number variants can be resolved by SNP genotyping arrays; and (4) subsets of gene families can be explored using SNP array data (see below). The disadvantages of GWAS are that there are no a priori assumptions about a possible connection to AIDS as there are for candidate genes; therefore, SNP association discovery must be complemented with additional function-based implication.

The large number of SNPs interrogated requires statistical correction for multiple testing, and to avoid false positives the significance threshold must be stringent. Yet mixed among the below-threshold SNPs are a few gems, such as those in CCR5 and KIR, whose presence in pathways associated with AIDS pathogenesis make them too good to miss (for instance, many ARGs in Table 1 are not revealed by GWAS). Finally, GWAS cannot resolve rare causal variants (f <5%).

Goldstein has suggested that rare variants may account for undiscovered genetic influences on AIDS and other complex diseases [42],[43], but these genetic variants would not be uncovered by GWAS. Although it is impossible to predict future discoveries with confidence, the frequent occurrence of deadly infectious disease episodes in human history has clearly provided abundant selective pressures (possibly raising allele frequencies for CCR5-Δ32, HB-S, DUFFY, HLA and others) elevating many disease immune defense alleles above the ‘rare allele’ frequency. We also suggest that the study design of some of the previous AIDS GWAS might be improved by assessing clinical endpoint/phenotypes less variable than viral load, set point and CD4 cell trajectory. Although viral load/set point are valid predictors of AIDS progression on a course scale, in our cohorts the signal suffers somewhat from noise, and is also less continuous than survival analyses (using Cox proportional hazards analyses for detecting ARGs that influence AIDS progression). Better approaches for resolving the true association signals that fall below genome-wide significance threshold are needed if we are to maximize the potential of AIDS GWAS, and will likely require the evaluation of gene associations from a variety of perspectives.

One recent example of a potentially ‘better approach’ is the recent GWAS that associated several SNPs within the large 1.1 Mbp PARD3B gene (chr2), a locus that regulates cell polarity in epithelial cells [40],[44]. Nine of the 15 lowest P-values in the GWAS fell in a short 5 kb LD block across a single PARD3B exon. One of the nine SNPs reached genome-wide significance ($P = 3.4 \times 10^{-8}$), while the others fell just below that threshold. The basis for the association (Figure 2) demonstrates that the rare genotype (GG) for the SNP almost never progress to AIDS, while people that are heterozygous for this SNP progress markedly slower than those homozygous for the common allele (CC). Support for the gene association came from six angles: (1) a nearly identical effect was observed among two distinct risk groups (hemophiliacs and gay men; Figure 2b,c); (2) the SNP association result was replicated, albeit with a weaker statistical strength ($P = 0.03$), in independent European cohorts; (3) one of the associated SNPs is a predicted exon splicing enhancer; (4) a quantitative measure of PARD3B splice products in lymphoblastoid B-cell lines with alternative PARD3B genotypes revealed a dominant 30 to 40% reduction in PARD3B isoform transcripts; (5) in the GWAS, PARD3B alleles explained 4.3% of the epidemiological variance of AIDS progression, higher than any of the other candidate genes in Table 1 similarly assessed in the same cohorts; (6) PARD3B gene products are known to interact with SMAD proteins, signal transduction modulators that mediate gene signaling, including through a direct interaction with HIV regulatory proteins [45]. Taken together, the cumulative replication, HIV1 regulatory connection, transcription influence and association data on PARD3B offers a plausible new genetic influence of AIDS progression.

**Beyond GWAS: new approaches**

The PARD3B study was intentionally limited to a single endpoint or phenotype (time of progression as defined by the AIDS 1987 Centers for Disease Control) to avoid statistical penalties for multiple tests. Yet many different gene association tests are possible with the rich clinical and genetic data we have collected across the years on these retrospective AIDS cohorts; indeed, many of these tests were performed and considered supportive in the previous candidate gene studies [7],[10] (Table 1). In spite of the aversion to multiple test statistical correction penalties, there is information than can be gleaned from detailed clinical data that should be explored. Hutcheson et al. [7] described useful heat plots that allow one to inspect the pattern of genetic association across many tests, as well as across small regions of the genome in strong LD. The combination of multiple non-independent statistical signals is a challenge to interpret, but in cases of known genes, such as CCR5-Δ32, HLA and IL10, the patterns are illuminating. The heat plots also provide a derivative approach to public data sharing of GWAS results without the problem of violating the informed consent and privacy constraints set out by Institutional Review Boards, which often restrict open access to human cohort data [46]. For example, posting an unabridged table of GWAS results online (odds ratios, P-values and confidence intervals), together with two-dimensional and three-dimensional visualization heat plots, would allow researchers to freely inspect the results of a published GWAS [40], in any genomic region they may discover in a different cohort, for independent replication purposes – without viewing patients’ confidential clinical or genotypic information.
Now that ten AIDS GWAS have been completed [11,30-41], it is important to share and compare these data to maximize the discoveries and minimize Type 1 (false positive) errors. Meta-analyses such as the International HIV Acquisition Consortium and the HIV Controllers Consortium are important advances that should be encouraged [35,47]. Further, most of the published studies with any statistical power involve European Caucasian patients. Newer cohorts in Africa and Asia would increase the chance of discovering adaptive variants that may have arisen in those ethnicities in recent centuries. Such cohort developments are ongoing with the CHAVI consortium [48], the Botswana Harvard Partnership [49] and the Chinese AIDS collaboration [50]. It is also important to expand interrogation of critical stages of HIV/AIDS by exome and whole genome sequence analyses to capture SNP variants that are not well represented in available genotyping arrays [51]. Whole genome sequencing will offer an unabridged assessment of gene variants in these cohorts and will likely reveal additional host factors that regulate AIDS pathogenesis.

A compromise approach between the specificity of candidate gene screens and the stringency of GWAS statistical thresholds is to explore certain candidate gene subsets represented within GWAS. This strategy limits the considered SNPs to specific subsets of candidate genes and lowers the multiple SNP test threshold for genome-wide significance. Hendrickson et al. [52] used this approach to explore the association of a group of human genes that are involved in mitochondrial metabolism, named nuclear encoded mitochondrial proteins (NEMPs) [53]. Mitochondrial metabolism is relevant because AIDS pathogenesis clearly involves mitochondrial deterioration and cell death, because mitochondrial toxicity has been linked to several adverse events of HAART, and because mitochondrial haplotypes appear to be associated with differential survival to AIDS in longitudinal cohorts [54-56].

Two tested NEMP-encoding genes displayed significant (corrected for all SNPs considered) genotypic influences...
on AIDS progression: peroxisomal D3,D2-enoyl-CoA isomerase (PECI) on chromosome 6 and acyl-CoA synthetase medium-chain family member 4 (ACSM4) on chromosome 12 (Table 1). The gene subset approach allowed the detection of gene associations that would have been discounted in an agnostic full GWAS since their P-values of association significance ($P = 6.5 \times 10^{-6}$ and $3.6 \times 10^{-6}$ for PECI and ACSM4, respectively) fall below a full GWAS P-value threshold.

Another GWAS subset explored was that of genes required for HIV infection of cultured human cells, termed HIV dependency factors (HDFs) [57]. In 2008, four siRNA-based in vitro studies were published that collectively identified several hundred HDF genes [58-61]. Chinn et al. [57] identified 6,380 SNPs that occurred within 278 HDF genes and used a subset of the PARD3B GWAS study data [40] to test them for gene associations with HIV infection, AIDS progression and AIDS-defining sequelae. SNP variants in two genes, NCOR2 (also known as SMRT) and IDH1, showed significant associations with HIV infection, consistent with their selection from HDF genes. IDH1 was particularly notable, first since its HDF status was one of a few replicated in independent HDF studies [58,59], and second because IDH1 can function as both a tumor suppressor (loss of isocitrate dehydrogenase 1 (IDH1) function) and an oncogene in human glioblastomas and other neoplasms [62-64].

The zinc finger ribbon domain 1 (ZNRD1) gene (located within the HLA locus) was one of the most strongly associated variants with HIV set point and disease progression in several GWAS [11,33]. ZNRD1 also appeared as a candidate gene in one HDF screen [58], while Chinn et al. [57] implicated this gene as being associated with both HIV acquisition and HIV progression. These multiple indications of AIDS influence using different approaches (GWAS, set point and survival analyses) together make a strong case for the influence of the ZNRD1 genotype on HIV/AIDS.

Conclusions
Thirty years of genomics investigation of AIDS has produced some important findings that have improved understanding of the disease and informed attempts to stem its deadly pace. Many host genes that affect AIDS have been postulated through candidate gene associations, GWAS, HDF analyses, molecular virology and other approaches. Many, but not all, of the implicated genes have been independently replicated by various approaches designed to overcome the statistical challenge posed by multiple tests (for example, CCR5-∆32, HLA, KIR, IDH1, ZFNR1 and others). Most important, at least five discoveries have led to bedside translation: (1) development of CCR5-∆32-based HIV entry inhibitor therapy [20,21]; (2) HLA-based pharmacogenomics screening for B*5701-mediated abacavir adverse events [27]; (3) clearing of HIV from the Berlin patient by a stem cell transplant from a CCR5-∆32/∆32 homozygous donor led to gene therapy trials of autologous CCR5-∆32 knockout in AIDS patients [22-24]; (4) use of the CCR5 antagonist, maraviroc, as GVHD prophylaxis in cancer patients receiving marrow and stem cell transplants [26]; and (5) IDH1 discoveries have stimulated the search for drugs that block the accumulation of 2-hydroxyglutarate for cancer [62-64]. These cancer-targeted pharmaceuticals may well equally inform HIV/AIDS therapies in the future.

The disappointments of the ARG searches are several. The total number of ARGs described account for less than 10 to 15% of the variance in AIDS progression and far less for other AIDS-associated measures: namely HIV acquisition, HAART outcomes or specific AIDS-defining conditions. This means that most of the determinants (whether genetic or non-genetic) are yet to be determined. The stringent statistical threshold for GWAS may force us to discount real variants that do not pass the genome-wide significance level; we need to develop a solution to this conundrum. In addition, genotyping arrays used to date, which contain between 500,000 and 1,000,000 SNPs, cover at best 10 to 15% of the variants in genes and gene regions that we want to interrogate, so we depend upon LD to detect the causal variants through inference. We are missing much of the common variation, especially that found outside of genes (such as in the recently described 4 million regulatory regions [65]), and nearly 100% of the rare variants. Finally, because present GWAS largely target European Caucasian ethnic groups, variants accumulated in other ethnicities have not been thoroughly screened.

The next generation of ARG GWAS will address and remedy these shortcomings as follows. Combined meta-analyses, such as the International HIV Acquisition Consortium [35,47], will help affirm the statistically uncertain discoveries that are robust. Subset analyses such as the HDF and NEMP groups described in this review will help here. In addition, better strategies for data sharing of large GWAS and association studies will go a long way to encourage independent inspection, replication and composite interpretations. Bigger genotyping arrays (for example, Illumina 2.5M Infinium arrays) will increase coverage greatly. By far the most comprehensive approach, whole genome sequencing, will accomplish this ever better, but cost is still the limiting factor for this strategy. Further, the development of large HIV/AIDS cohorts in Africa and Asia suitable for GWAS and genome sequence analyses will be welcome additions to the screening of variants for important clinically relevant ARGs [48-50].

Finally, genomics is but one of several players in AIDS research and there are some extremely promising
developments outside our field that must be mentioned. First, it is now well demonstrated that circumcision is a powerful protective aspect of HIV acquisition that is being implemented widely in the developing world to decrease the spread of HIV [66,67]. Second, three recent clinical trials have demonstrated a powerful near absolute protection against HIV infection among high-risk gay men and heterosexuals who took a single daily combination anti-retroviral pill (such pre-emptive treatment strategies are termed pre-exposure prophylaxis (PrEP)) [68,69]. In a large global cohort of 2.499 men who have sex with men, those treated with Truvada (a combination of two anti-retroviral agents, tenofovir and emtricitabine) showed a 48% reduction in HIV acquisition; this jumped to 95% protection when only those whose drug-taking compliance was 100% were considered [68]. Similar results were observed in an African trial where PrEP-treated heterosexual at-risk women were studied [69]. Anti-retroviral microbicides are also making progress: two recent trials demonstrated 80% reduction in transmission among compliant study participants [70]. Last, in what may be his greatest legacy, former US President George W. Bush established the President’s Emergency Plan for AIDS Relief (PEPFAR) in 2002, offering US$15 billion in federal aid for treatment of HIV-infected people across the developing world. He added US$48 billion to the program in 2008. In 2002 there were less than 300,000 people on HAART in the developing world but today, thanks to PEPFAR, there are 6.6 million people on HAART. President Obama has continued PEPFAR funding and there is now tangible hope for slowing the spread of this contagion through education, treatment and research. By interdisciplinary application of important advances, the real dream is to one day see a generation of people that are free from AIDS.

**Abbreviations**

ARG: AIDS restriction gene; CCR5: C-C chemokine receptor; CHAVI: Center for HIV/AIDS Vaccine Immunology; GVHD: graft versus host disease; GWAS: genome-wide association study; HAART: highly active anti-retroviral therapy; HIV: HIV dependency factor; HDF: HIV dependency factor; LD: linkage disequilibrium; NEMP: nuclear encoded mitochondrial protein; PEPFAR: President’s Emergency Plan for AIDS Relief; PrEP: pre-exposure prophylaxis; SNP: single nucleotide polymorphism; WINN: West Nile virus.

**Author details**

1. Theodosius Dobzhansky Center for Genome Bioinformatics, 41A Sredniy Avenue, St Petersburg State University, St Petersburg, 199034, Russia.
2. Department of Biology, Shepherd University, P.O. Box 5000, Shepherdstown, West Virginia 25443-5000, USA.

Published: 31 January 2013

**References**

1. Pneumocystis pneumonia – Los Angeles. MMWR Morb Mortal Wkly Rep 1981, 30:250–252.
2. Kaposi’s sarcoma and pneumocystis pneumonia among homosexual men – New York City and California. MMWR Morb Mortal Wkly Rep 1981, 30:305–308.
3. World Health Organization. Global Health Observatory Data Repository, Life Expectancy [http://apps.who.int/ghodath/xid=710965D]
4. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, Funke R, Gage D, Harris K, Keaford A, Howland J, Kann L, Lehoczky J, LeVine R, McKean P, McMichael K, Meldrid J, Mesirov JP, Miranda C, Morris W, Naylor J, Raymond C, Rosetti M, Santos R, Sheridan A, Sougnez C, et al.: Initial sequencing and analysis of the human genome. Nature 2001, 409:880–921.
5. An F, Winkler CA. Host genes associated with HIV/AIDS: advances in gene discovery. Trends Genet 2010, 26:119–31.
6. Carrington M, O’Brien SJ. The influence of HLA genotype on AIDS. Ann Rev Med 2003, 54:535–551.
7. Hutcheson H, Lateurenberger J, Nelson G, Pontius JS, Kessing BD, Smith MW, Johnson R, Stephens B, Phair J, Goedert J, Donfield S, O’Brien SJ. Detecting AIDS restriction genes: from candidate genes to genome-wide association discovery. Vaccine 2008, 26:2951–2965.
8. Fellay J, Shinnna KV, Teleni, Goldstein DB. Host genetics and HIV-1: The final phase? PLoS Pathog 2010, 6:s1001083.
9. Lederman MM, Alter G, Daskalakis DC, Rodriguez B, Sieg SF, Hardy G, Cho M, Anthony D, Harding C, Weinberg A, Silverman RH, Douek DC, Margolix J, Goldstein DB, Carrington M, Goedert JJ. Determinants of protection among high-risk HIV seronegative persons – an overview. J Infect Dis 2010, 202:S33–S38.
10. O’Brien SJ, Nelson GW. Human genes that limit AIDS. Nat Genet 2004, 36:565–574.
11. Fellay J, Shinnna KV, Ge D, Colombo S, Ledergerber B, Weale M, Zhang K, Gumbs C, Castagna A, Coszaraiso A, Cozi-Lepi A, De Luca A, Easterbrook P, Francipoli P, Malali S, Martinez-Picado J, Miro JM, Obel N, Smith JW, Wynnger J, Descomes P, Antonarasik SE, Letvin NL, McMichael AJ, Haynes BF, Teleni A, Goldstein DB. A whole-genome association study of major determinants for host control of HIV-1. Science 2007, 317:944–947.
12. Dean M, Carrington M, Winkler C, Hutley GA, Smith MW, Allikrens R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vahovd D, Kaskow R, Saah A, Rinaldo C, Detels R, O’Brien SJ. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CCR5 structural gene. Science 1996, 273:1856–1862.
13. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragostì, Lapoumenolde C, Cogniaux J, Forencie C, Mulyederrans G, Verhoefste C, Burtonboy G, Georges M, Ima-It Rana S, Xi Y, Smyth RJ, Collman RG, Doms RW, Vassart G, Parmentier M. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR5 chemokine receptor gene. Nature 1996, 382:722–725.
14. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koop RA, Landa NR. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996, 86:367–377.
15. Fella S, O’Brien SJ, Nelson GW: Human immune deficiency virus type-1. Curr Med Chem J Antimicrob Chemother 2006, 13:2369–2384.
16. Hendrickson SL, Jacobson LP, Nelson G, Phair JP, Johnson R, Margolick JB, Detels R, Rinaldo C, O’Brien SJ. Host genetic influences on highly active antiretroviral therapy efficacy and AIDS-free survival. J Acquir Immune Defic Syndr 2008, 48:263–271.
17. Murphy PM: International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature. Pharmacol Rev 2002, 54:227–229.
18. O’Brien SJ, Dean M: In search of AIDS-resistance genes. So Am 1997, 277:44–51.
19. Manfredi R, Sabbatani S: A novel antiretroviral class (fusion inhibitors) in the management of HIV infection. Present features and future perspectives of enfuviride (T-20). Curr Med Chem 2006, 13:2369–2384.
20. Aquaro S, D’Antigo R, Sivicher V, Peri GD, Caputo SL, Viisco-Comandini U, Santoro M, Bertoli A, Mazzastra F, Bonora S, Tozzi V, Bellagamba R, Zaccarelli M, Narciso P, Antoni A, Perino CF: Specific mutations in HIV-1 gp120 are associated with immunological success in HIV-1-infected patients receiving enfuviride treatment. J Antimicrob Chemother 2006, 58:714–722.
21. Dorf P, Westby M, Dobbs S, Griffin P, Irvine B, Macarey M, Mori J, Rickett G, Smith-Burchell C, Napier C, Webster R, Armour D, Price D, Stammen B, Wood A, Perros M. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
Evidence for the cure of HIV infection by CCRI3467/32 stem cell transplantation. N Engl J Med 2009, 360:692–698.

Allers K, Hutter G, Hofmann, J. Loddenkemper C, Rieger K, Thiell E, Schneider: Epistatic interaction between KIRDS1 and HLA-B delays the progression to AIDS. Nat Genet 2002, 31:429–434.

Martin MP, Gao X, Lee HL, Nelson G, Detels R, Goedert J, Buchbinder S, Hoits K, Vahov D, Trowdse J, Wilson M, O’Brien SJ, Carrington M. Epistatic interaction between KIRDS1 and HLA-B delays the progression to AIDS. Nat Genet 2002, 31:429–434.

Crawford G, Sullivan J, Gonzalez E, Davies L, Camargo A, Moore JM, Beattie N, Ratsimandresy R, Montes M, van Wout AB, Gottlieb CA, Gershwin A, Rouzioux C, Dalfy J, Lévy J, Herbeng S, Dina C, Phair J, Donfield S, Goedert J, Buchbinder S, Terada J, Schachter F, Grolleau F, Mullins J. Multiple-cohort genetic association study identifies a locus at 1q41 associated with rate of HIV-1 disease progression to clinical AIDS. J Infect Dis 2010, 201:618–626.

Limoso S, Coulonges C, Herbeck JT, van Manen D, An P, Le Clerc S, Delaneau O, Diop G, Taing L, Montes M, van Wout AB, Gottlieb CA, Therawath A, Rouzioux C, Dalfy J, Lévy J, Herbeng S, Dina C, Phair J, Donfield S, Goedert J, Buchbinder S, Terada J, Schachter F, Grolleau F, Mullins J. Multiple-cohort genetic association study reveals CXCR6 as a new chemokine receptor involved in long-term nonprogression to AIDS. J Infect Dis 2010, 202:908–915.

Pelak K, Goldstein DB, Wallermy NM, Felliay J, De C, Gao X, Maia JM, Cronin KD, Hussain SX, Carrington M, Michael NL, Weinablo AC. Infectious Disease Clinical Research Program HIV-Working Group. National Institute of Allergy and Infectious Diseases Center for HIV/AIDS Vaccine Immunology (CHAVI). Host determinants of HIV-1 control in African Americans. J Infect Dis 2010, 201:1141–1149.

Troyer JL, Nelson GW, Lautenberger JA, Chinni L, McIntosh C, Johnson RC, Sezgin E, Kissing B, Malasky M, Hendrickson SL, Li G, Pontius J, Tang M, An P, Winkler CA, Limosu S, Le Clerc S, Delaneau O, Zaguery JF, Schuitemaker H, van Manen D, Beamer JH, Gomperts ED, Buchbinder S, Goedert J, O'Brien SJ. Genome-wide association study implicates PARDDB-related AIDS restriction. J Infect Dis 2011, 203:491–502.

Limoso S, Delaneau O, van Manen D, An P, Sezgin E, Le Clerc S, Coulonges C, Troyer JL, Veldhijn JH, van den Berg LH, Spadoni J, Taing L, Labit T, Montes M, Dalfay J, Schachter F, Bronje SJ, Buchbinder S, van Netra ML, Jabs DA, Frolig P, Schuitemaker H, Winmen CA, Zaguery JF. Multicohort genomewide association study reveals a new signal of protection against HIV-1 acquisition. J Infect Dis 2012, 205:1155–1162.

Goldstein DB. Common genetic variation and human traits. New Engl J Med 2009, 360:1696–1698.

Cirilli ET, Goldstein DB. Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat Rev Genet 2010, 11:415–425.

Koijima M, Noda Y, Takeya R, Sato N, Takeuchi K, Sumimoto H. PAR3beta, a novel homologue of the cell polarity protein PAR3, localizes to tight junctions. Biochem Biophys Res Comm 2002, 299:5715–5719.

Arabam S, Sawaya BE, Safik A, Batuman O, Khalili K, Alimi B. Multiple COG-1 gene transcription by Smads and HIV-1 Tat in human glial cells. Mol Microbiol 2003, 49:915–927.

Kovacs JS, Goldstein DB, Center for HIV/AIDS Vaccine Immunology, Common human genetic variants and HIV-1 susceptibility: a genome-wide survey in a homogeneous African population. AIDS 2011, 25:513–518.

Westerv C, Eden SK, Shepherd BE, Bussmann H, Navtrivv Y, Samuels DC, Hendrickson SL, Winkler CA, O'Brien SJ, Essex M, DMaiaquill R, Degruttola V, Marlink RC. Risk factors for symptomatic hyperalcalatia and lactic acidosis among combination antiretroviral therapy-treated adults in Botswana: results from a clinical AIDS Ret Hormone Res 2012, 78:245–255.

Yu XF, Liu W, Chen J, Kong W, Liu B, Zhu Q, Liang F, McCutchan F, Pyasysrilo S, Lai S. Maintaining low HIV type 1 env genetic diversity among injection drug users infected with an B.c recombinant and CRF01_AE HIV type 1 in a multicenter China. AIDS Res Hum Retrovirol 2002, 16:167–170.

Cirilli ET, Singh A, Shannan KV, Gao X, Shi J, Maia JM, Heinen ET, Goedert JJ, Goldstein DB. Center for HIV/AIDS Vaccine Immunology (CHAVI). Screening the human exome: a comparison of whole genome and whole transcriptome sequencing. Genome Biol 2010, 11:R57.

Hendrickson SL, Lautenberger J, Chinni L, Phair J, Goedert JJ, Vahov D, Donfield SF, Buchbinder SB, Troy J, O'Brien SJ. Genetic variants in nuclear-encoded mitochondrial genes influence AIDS progression. PloS One 2010,
LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Abdool K in Women. Clinical trial 
S New Engl J Med
Casapia M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, a randomised trial.
2007, 657–666. 
Lancet
Wawer MJ: Male circumcision for HIV prevention in men in Rakai, Uganda: young men in Kisumu, Kenya: a randomised controlled trial. 
Male circumcision for HIV prevention in 
Baile 489: An integrated encyclopedia of DNA elements in the ENC
926–928. 
J Nat Cancer Inst 
207: 339–344. 
J Exp Med
metabolite 2-hydroxyglutarate accumulates in acute myelogenous 
Jin S, Schenkein DP, Su SM, Dang L, Fantin VR, Mak TW: Gr human glioblastoma multiforme. 
2008, 1807–1812. 
Science
Papadopoulos N, Parmigiani G, An integrated genomic analysis of 
RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, P
19473. 
J Biol Chem
284: 1836–1845. 

60. Zhou H, Xu M, Huang Q, Gates AT, Zhang XD, Castle JC, Stec E, Ferrer M, Strulovic B, Hauzeda DJ, Epseaset AS. Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe 2008, 4:495–504. 
61. Yeung ML, Houzet L, Yesodiss VS, Jean KT. A genome-wide short hairpin RNA screening of jurkat T-cells for human proteins contributing to productive HIV-1 replication. J Biol Chem 2009, 284:19463–19473. 
62. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angelendt P, Maniko P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Ker S, Nikolitskaya T, Nikolksy Y, Busam DA, Tekiea H, Daza LA, Hartjan J, Smith DR,Strauberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, et al: An integrated genomic analysis of humanogloblastoma multiforme. Science 2008, 321:1807–1812. 
63. Gross S, Cañas RA, Minden MD, Driggers EM, Birthing MA, Jang HG, Sasaki M, Jin S, Schenken DF, Su SM, Dang L, Fantr VM, Mak TC: Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 2010, 210:339–344. 
64. Garber K. Oncometabolite? IDH1 discoveries raise possibility of new oncometabolites in brain cancers and leukemia. J Nat Cancer Inst 2010;92(6):926–928. 
65. ENCODE Project Consortium, Bernstein BE, Birney E, Dunham I, Green ED, Gunter C, Snyder M. An integrated encyclopedia of DNA elements in the human genome. Nature 2012, 489:52–74. 
66. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JJN, Williams CF, Campbell RT, Ndinya-Achola JO. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007, 369:643–656. 
67. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watia S, Nalugoda F, Kiwanuka N, Moulton LH, Chaudhary MA, Chen MZ, Sewankambo NK, Wabwire-Mangen F, Bacon MC, Williams CF, Opendik P, Reynolds JK, Laiyendeker CK, Quinn TC, Wavber MJ. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007, 369:657–666. 
68. Grant RM, Lama JR, Anderson PL, Mcshahan V, Liu Y, Vargas L, Gcocipea C, Casapia M, Guanira-Carranza JV, Ramirez-Carilda ME, Montoya-Herrera O, Fernando T, Veloso VG, Buchbinder SP, Charyalatsk S, Schechter M, Becker LG, Mayer KH, Davis ES, Arico KV. Preexposure chemoprophylaxis for men who have sex with men. New Engl J Med 2010, 363:2587–2599.
69. Safety and Effectiveness of Tenoforiv 1% Gel, Tenoforiv Disoprifor Fumarate, and Entritcimetabine/Tenoforiv Disoprifor Fumarate Tablets in Preventing HIV in Women. Clinical trial [http://clinicaltrials.gov/ct2/show/NCT00705679].
70. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Khansary AB, Sibeiso S, Miliana M, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D, CAPRSA 004 Trial Group: Effectiveness and safety of tenoforiv gel, an antiretroviral microphone, for the prevention of HIV infection in women. Science 2010, 329:1168–1174.
71. Carrington M, Kissner T, Gerrard B, Ivanos S, O'Brien SJ, Dean N, Novel alleles of the chemokine-receptor gene CCR5. Am J Hum Genet 1997, 60:261–267.
72. Stephens JC. Dating the origin of the CCR5-∆32 AIDS resistance gene allele by the coalescence of haplotypes. Am J Hum Genet 1998, 62:1507–1515.
73. Bambshad MJ, Mummidi S, Gonzalez E, Ahuja SS, Dunn DM, Watkins WS, Wooding S, Stone AC, Jorde LB, Weiss RB, Ahuja SK. A strong signature of balancing selection in the S’ cis-regulatory region of CCR5. Proc Natl Acad Sci U S A 2002, 99:10393–10394.
74. Saberi PC, Walsig E, Schaffner S, Varailly P, Fry B, Cullen M, Mikkelsen T, Roy J, Patterson N, Cooper R, Althulder D, Lander ES. The case for selection at CCR5Δ32. PLoS Biol 2005, 3:1963–1969.
75. Elvin SJ, Williamson ED, Scott JC, Smith JN, Perez De Lema G, Chilla S, Clapham P, Pfeffer K, Schlondorf D, Luckow B. Evolutionary genetics: Ambiguous role of CCR5 in Y pestis infection. Nature 2004, 430:417–424.
76. O'Brien SJ. Tears of the Cheetah and Other Tales from the Genetic Frontier. St Martin’s Press: New York; 2003.
77. Gask WG, Lim JK, Cholera R, Pietnet AG, Gao JL, Murphy PM: Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J Exp Med 2005, 202:1087–98.
78. Gask WG, McDermott DH, Lim JK, Kelekong S, Tu SF, Frank WA, Pape J, Cheshier SH, Murphy PM: CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 2006, 203:33–40.
79. O'Brien SJ, Moore J. The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol Rev 2000, 177:99–111.
80. Smith MW, Dean M, Carrington M, Winker C, Hurtable GA, Lomb DA, Goedert JJ, O'Brien TR, Jacobson LP, Kaslow R, Buchbinder S, Wittinghoff E, Vahov D, Hoets K, Hilgarten MW, O'Brien SJ. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Science 1997, 279:959–965.
81. Martin MP, Dean M, Smith MW, Winker C, Gerrard B, Michael NL, Lee B, Doms RW, Margolick J, Buchbinder S, Goedert J, O'Brien TR, Hilgarten MW, Vahov D, O'Brien SJ, Carrington M. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 1996, 272:1907–1911.
82. Winkler C, Modri W, Smith MW, Nelson GW, Wu X, Carrington M, Dean M, Honjo T, Tashiro K, Yabe D, Buchbinder S, Wittinghoff E, Goedert J, O'Brien TR, Jacobson LP, Detels R, Donfield S, Willoughby A, Gomperts E, Vahov D, Phair J, O'Brien SJ. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. Science 1998, 279:389–393.
83. Carrington M, Nelson GW, Martin MP, Kissner T, Vahov D, Goedert J, Kaslow R, Buchbinder S, Hoots K, Donfield S, Willoughby A, O'Brien SJ, Smith MW. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci U S A 2000, 97:14467–14472.
84. Gao X, Nelson GW, Karacic P, Martin MR, Piar J, Kaslow R, Goedert JI, Buchbinder S, Hoots K, Vahov D, O'Brien SJ. Carrington M. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. New Engl J Med 2001, 344:1668–1675.
85. An P, Nelson GW, Wang L, Donfield S, Goedert JI, Phair J, Vahov D, Buchbinder S, Farrar WL, Modi W, O'Brien SJ, Winkler CA. Modulating influence on HIV/AIDS by interacting RANTES gene variants. Proc Natl Acad Sci U S A 2002, 99:10002–10007.
86. Modi WS, Goedert J, Strathdee SA, Buchbinder S, Detels R, Donfield S, Willoughby A, O'Brien SJ, Smith MW. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci U S A 2000, 97:14467–14472.
87. Gao X, Nelson GW, Karacic P, Martin MR, Piar J, Kaslow R, Goedert JI, Buchbinder S, Hoots K, Vahov D, O'Brien SJ, Carrington M. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. New Engl J Med 2001, 344:1668–1675.
91. An P, Bleiber G, Duggal P, Nelson G, May M, Mangeat B, Alobwede I, Trono D, Vlahov D, Donfield S, Goedert JJ, Phair J, Buchbinder S, O’Brien SJ, Telenti A, Winkler CA: APOBEC3G genetic variants and their influence on the progression to AIDS. J Virol 2004, 78:11070–11076.
92. Martin MP, Lederman MM, Hutcheson HB, Goedert JJ, Nelson GW, van Kooyk Y, Detels R, Buchbinder S, Hoats K, Vlahov D, O’Brien SJ, Carrington M: Association of DC SIGN promoter polymorphisms with increased risk for parenteral but not mucosal acquisition of HIV-1 infection. J Virol 2003, 78:14053–14056.
93. Gao X, Bashirova A, Iversen AK, Phair J, Goedert JJ, Buchbinder S, Hoats K, Vlahov D, Atfield M, O’Brien SJ, Carrington M: AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. Nat Med 2006, 11:1290–1292.
94. Bashirova AA, Bleiber G, Qi Y, Hutcheson H, Yamashita T, Johnson RC, Cheng J, Alter G, Goedert JJ, Buchbinder S, Hoats K, Vlahov D, May M, Maldarelli F, Jacobson L, O’Brien SJ, Telenti A, Carrington M: Consistent effects of TSG101 genetic variability on multiple outcomes of exposure to human immunodeficiency virus type 1. J Virol 2006, 80:6757–6763.
95. Javanbakht H, An P, Gold B, Petersen DC, O’Huigin C, Nelson GW, O’Brien SJ, Kirk GD, Detels R, Buchbinder S, Donfield S, Shulenin S, Song B, Perron MJ, Stremlau M, Sodroski J, Dean M, Winkler C: Effects of human TRIM5alpha polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection. Virology 2006, 354:15–27.
96. An P, Duggal P, Wang LH, O’Brien SJ, Donfield S, Goedert JJ, Phair J, Buchbinder S, Kirk GD, Winkler CA: Polymorphisms of CUL5 area associated with CD4+ T cell loss in HIV-1 infected individuals. PLoS Genet 2007, 3:e19.
97. An P, Wang LH, Hutcheson-Dilks H, Nelson G, Donfield S, Goedert JJ, Rinaldo CR, Buchbinder S, Kirk GD, O’Brien SJ, Winkler CA: Regulatory polymorphisms in the cyclophilin A gene, PPIA accelerate progression to AIDS. PLoS Pathog 2007, 3:e849–e857.
98. Welzel TM, Gao X, Pfeiffer RM, Martin MP, O’Brien SJ, Goedert JJ, Carrington M, O’Brien TR: HLA Bw4 alleles and HIV-1 transmission in heterosexual couples. AIDS 2007, 21:225–229.
99. Hendrickson SL, Jabs DA, Van Natta M, Lewis RA, Wallace DC, O’Brien SJ: Mitochondrial haplogroups are associated with risk of neuroretinal disorder in HIV-positive patients. J Acquir Immune Defic Syndr 2010, 53:451–455.
100. An P, Johnson R, Phair J, Kirk GD, Yu XF, Donfield S, Buchbinder S, Goedert JJ, Winkler CA: APOBEC3B deletion and risk of HIV-1 acquisition. J Infect Dis 2008, 200:1054–1058.
101. O’Brien SJ, Nelson GW, Winkler CA, Smith MW: Polygenic and multifactorial disease gene association in man: lessons from AIDS. Ann Rev Genet 2000, 34:563–591.

doi:10.1186/gb-2013-14-1-201
Cite this article as: O’Brien SJ, Hendrickson SL: Host genomic influences on HIV/AIDS. Genome Biology 2013, 14:201.